Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin TrialPR Newswire • 24 days ago
Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for...
Share to Feed
The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a...
Psyence Biomedical gets non-compliance notification from Nasdaq...
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the Company ) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental...
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in...
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence Group" or the "Company") (CSE:PSYG) of the closing (the "Closing") of the business combination...
Gagnants
Le titre Psyence Biomedical (NASDAQ:PBM) a grimp vendredi de 146,36% 3,13 dollars lors de la session ordinaire.
L'action Ainos (NASDAQ:AIMD) a grimp de 88,36% 2,11 dollars.
Le titre...
Titoli in rialzo
Il titolo Psyence Biomedical (NASDAQ:PBM) ha osservato un incremento del 140,94% a 3,06 dollari durante la sessione regolare di venerd .
Il titolo Ainos (NASDAQ:AIMD) ha avuto un...